Theodore Harris

Chief Executive Officer, President & Chairman, BALCHEM CORP -CL B

Search every verified Theodore Harris interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Theodore Harris, Chairman, President, and CEO of Balchem Corporation, participated in the company’s second quarter 2026 earnings call on July 30, 2026. During the call, Harris reported record consolidated revenue of $284 million, an 11.2% increase year-over-year, and adjusted EBITDA of $78 million, up 12.6%. He noted that the quarter marked the company’s 28th consecutive period of year-over-year adjusted EBITDA growth. Harris also highlighted that management attributed higher manufacturing input costs to the conflict in the Middle East, which partially offset gross margin expansion. Harris discussed the company’s capital allocation activities, stating that Balchem repurchased approximately $29 million of its common stock during the quarter and $114 million over the trailing twelve months. He also mentioned that the company increased its borrowing capacity to $650 million through 2031 to support innovation, capacity expansion, and strategic acquisitions. In his remarks, Harris emphasized the importance of scientific evidence and product differentiation when evaluating potential nutrient investments, citing the acquisition of Kappa Solutions and its patented encapsulated vitamin K2 as an example. He also noted that the company’s nutrient products remain relatively underpenetrated at about 20% market penetration, with growth driven primarily by volume.